Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
Epistemonikos ID: 3964b9a16e51f3b7de0d13d9b733ebc4d7cc792f
First added on: May 05, 2024